Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

Desai, Hardik D; Sharma, Kamal; Shah, A; Patoliya, Jaimini; Patil, Anant; Hooshanginezhad, Zahra; Grabbe, Stephan; Goldust, Mohamad

doi:10.1111/jocd.14521

Cited by 37 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, COVID-19 vaccination was reported as a triggering factor of HZ. 8 Iwanaga et al 9 reported 399 cases of HZ after receiving the vaccine of COVID-19. There might be a link between COVID-19 vaccine and HZ emergence; however, the mechanism is still unknown.…”

Section: Discussionmentioning

confidence: 99%

“… 11 Similarly, HZ was detected in cases of COVID vaccination within first week to the fourth week of vaccination with mean period between HZ and COVID-19 vaccination was 7.64 days. 8 …”

Section: Discussionmentioning

confidence: 99%

“…5,9,10 The possible risk factors for development of HZ after COVID-19 vaccine include the decrease in immune response associated with old age of the patient, HIV infection, physical trauma, iatrogenic immunocompromission, or comorbid conditions such as malignancy or chronic kidney or liver disease. 8…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Is COVID-19 infection triggering oral herpes zoster? A case report

Saleh

Ata

Elashry

2021

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Patients affected with COVID-19 are at risk of developing serious and life-threatening conditions. The clinical manifestations of COVID-19 were detected in asymptomatic cases to severe clinical symptoms with a major impact on the respiratory system. A few cases of cutaneous as well as an oral lesion of herpes zoster in patients with COVID-19 were reported in the literature. We present a case of the rapid appearance of the oral lesion as a manifestation of herpes zoster associated with COVID-19 infection. Our case highlights the importance of oral examination as well as oral care in patients with COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 11 Similarly, HZ was detected in cases of COVID vaccination within first week to the fourth week of vaccination with mean period between HZ and COVID-19 vaccination was 7.64 days. 8 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is COVID-19 infection triggering oral herpes zoster? A case report

Saleh

Ata

Elashry

2021

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…Las vacunas disponibles en nuestro país son BBIPB – Corv (Sinopharm), BNT162b2 (Pfizer-BioNTech) y ChAdOx1-S (AstraZeneca) 3 . Aunque todavía, se desconocen los posibles efectos adversos a largo plazo de esta nueva generación de vacunas, los efectos secundarios comunes relacionados con la vacunación incluyen el dolor, enrojecimiento y/o hinchazón en el lugar de la inyección, fatiga, cefalea, fiebre y escalofríos 4 . (See Tabla 1 .)…”

Section: Introductionunclassified

“…Los efectos adversos más comunes a las vacunas son dolor en el sitio de inyección, fiebre, dolor de cabeza, náuseas y vómitos 4 . La aparición de herpes zóster después de la administración de alguna vacuna es un hallazgo que no es frecuente hallar en la literatura 1 , pero se han descrito casos de herpes zóster tras la vacunación de vacunas inactivadas contra la influenza, hepatitis A, rabia y encefalitis japonesa 7 .…”

Section: Introductionunclassified

Reactivación del virus varicela zóster tras la vacunación contra la COVID-19

López

Saldaña

2022

Piel

View full text Add to dashboard Cite

Persistent varicella zoster virus infection following mRNA COVID‐19 vaccination was associated with the presence of encoded spike protein in the lesion

Yamamoto

Kase

Sano

et al. 2022

J Cutaneous Imm & Allergy

View full text Add to dashboard Cite

Background Since the campaign of vaccination against COVID‐19 was started, a wide variety of cutaneous adverse effects after vaccination has been documented worldwide. Varicella zoster virus (VZV) reactivation was reportedly the most frequent cutaneous reaction in men after administration of mRNA COVID‐19 vaccines, especially BNT162b2. Aims A patient, who had persistent skin lesions after BNT162b2 vaccination for such a long duration over 3 months, was investigated for VZV virus and any involvement of vaccine‐derived spike protein. Materials & Methods Immunohistochemistry for detection of VZV virus and the spike protein encoded by mRNA COVID‐19 vaccine. PCR analysis for VZV virus. Results The diagnosis of VZV infection was made for these lesions using PCR analyses and immunohistochemistry. Strikingly, the vaccine‐encoded spike protein of the COVID‐19 virus was expressed in the vesicular keratinocytes and endothelial cells in the dermis. Discussion mRNA COVID‐19 vaccination might induce persistent VZV reactivation through perturbing the immune system, although it remained elusive whether the expressed spike protein played a pathogenic role. Conclusion We presented a case of persistent VZV infection following mRNA COVID‐19 vaccination and the presence of spike protein in the affected skin. Further vigilance of the vaccine side effect and investigation for the role of SP is warranted.

show abstract

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 37 publications

References 31 publications

Is COVID-19 infection triggering oral herpes zoster? A case report

Is COVID-19 infection triggering oral herpes zoster? A case report

Reactivación del virus varicela zóster tras la vacunación contra la COVID-19

Persistent varicella zoster virus infection following mRNA COVID‐19 vaccination was associated with the presence of encoded spike protein in the lesion

Contact Info

Product

Resources

About